• BiondVax just signed an exclusive worldwide license agreement with the Max Planck Society to develop and commercialize innovative NanoAb therapeutics for the treatment of psoriasis and psoriatic arthritis
• Part of an ongoing broad-based collaboration targeting therapies addressing diseases such as Covid-19, asthma, and macular degeneration
• Per BiondVax’s CEO, Amir Reichman, this exclusive license presents an exciting opportunity to develop a unique treatment for psoriasis

BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products mainly for treating infectious and autoimmune diseases, just announced that it has signed an exclusive worldwide license agreement to develop and commercialize VHH antibodies (“NanoAbs”) that target Interleukin-17 (“IL-17”). The license agreement is part of a broad-based collaboration with the Max Planck Society and the University of Medical Center Göttingen (“UMG”). The NanoAbs will be targeted toward the treatment of several relevant indications, including, but not limited to, psoriasis and psoriatic arthritis (https://ibn.fm/zifs4).

BiondVax’s collaboration with the Max Planck Institute for Multidisciplinary Sciences and UMG, both based in Germany, is producing a pipeline of innovative therapies addressing diseases underserved by current treatments, yet with large and growing markets. Previous development efforts have addressed diseases such as Covid-19, and BiondVax’s current venture with these two institutions is geared towards creating NanoAbs that target the large, underserved market of psoriasis, a chronic autoimmune disease that causes inflammation and scaling of the skin.

The condition affects over 7.5 million adults in the U.S. and an estimated 125 million people worldwide, yet currently available monoclonal antibodies (“mAbs”) therapies for the condition require an inconvenient systemic injection every four to eight weeks and come with adverse side effects, including exacerbation of Inflammatory Bowel Disease (“IBD”) (https://ibn.fm/rwg69). With BiondVax’s NanoAbs, it is possible to target not only IL-17A but also IL-17F and IL-17A/F complex, potentially generating superior efficacy in treating the condition.

Mr. Amir Reichman, BiondVax’s CEO, has lauded this exclusive license agreement, expressing his optimism that the company’s NanoAbs have the potential to provide a much-needed and vastly improved treatment option. He also termed it as a validation of the productivity of the collaboration among the three parties.

“The license of the IL-17 NanoAb from Max Planck is not only an exciting opportunity to develop a unique treatment for psoriasis and other autoimmune diseases but another validation of the productivity of our collaboration with Max Planck and UMG and portends additional significant developments to follow,” he noted.

According to Dr. Dieter Link, patent and licensing manager at Max Planck Innovation, this milestone marks a significant step toward the clinical application of the next VHH antibody candidates out of the larger group of NanoAbs contemplated by the collaborators.

“We are very pleased that the next antibody candidates out of a larger group pursued by the collaborators have successfully been generated, discovered, and characterized by the Max Planck Institute of Multidisciplinary Sciences,” he noted.

“BiondVax is well positioned to move this closer to and into clinical application,” he added.

BiondVax’s NanoAb platform has proven to have the potential to address a growing range of unmet medical needs. The company remains committed to developing innovative therapies that improve patients’ lives, with the recent exclusive Max Planck license key evidence of the potential for success in achieving BiondVax’s important goals.

For more information, visit the company’s website at www.BiondVax.com.

NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://ibn.fm/BVXV

• Electronic Servitor Publication Network recently signed a client agreement with Investor Brand Network (“IBN”), providing access to its managed digital engagement and activation services
• The agreement seeks to enhance IBN’s growth by helping the company reach new target markets to promote its brands and content distribution network
• XESP provides digital engagement and activation solutions that use sophisticated data analysis and smart technology, providing client companies with the ability to maintain complete control of their content while creating meaningful relationships with new customers
• The company helps clients drive growth

Electronic Servitor Publication Network (OTCQB: XESP), a growth-focused digital activation and engagement solutions innovator and provider targeting B2B companies, recently announced the signing of a client agreement with Investor Brand Network (“IBN”), a multifaceted financial news and publishing company consisting of more than 60 trusted investor-facing brands (https://ibn.fm/a0nBS).

The agreement seeks to enhance IBN’s growth by enabling the company to reach deeper into their current target markets and to access new markets. IBN gains full access to XESP’s managed digital engagement and activation services, including the proprietary Digital Engagement Engine(TM), to promote its brands and content distribution network of more than 5,000 key syndication outlets that help generate greater awareness for its clients.

“We are excited about our relationship with IBN, the clear service and thought leader in their field, to help them achieve their growth goals. We also look forward to exploring the synergies and new opportunities that our partnership will undoubtedly provide for XESP,” said Peter Hager, CEO of Electronic Servitor Publication Network.

Founded in October 2021, XESP is at the forefront of the digital transformation that is taking over B2B markets. XESP has positioned itself as the go-to company for clients looking for growth through optimizing their digital contact with target audiences in non-face-to-face situations. The company has developed a sophisticated technology stack that, coupled with its proven processes and workflows, provides real time data to client companies, enabling a dynamic and personalized connection between them and their target audiences.

“And in the end, it’s all about growth,” said Hager in a recent interview with Proactive Investors (https://ibn.fm/7nnFh). This is because XESP drives better interactions, facilitating better results for its clients. It also solves content management and optimization deficiencies in a fast-moving economy and market, thus guaranteeing its relevance. Moreover, XESP helps its customers preserve margins through efficiency.

One of the solutions in this technology stack is the Digital Engagement Engine(TM). The company’s website explains that this technology “utilizes a combination of automation, unique data management, and a modern workflow built on a microservices architecture to achieve greater reach and lift for content providers (https://ibn.fm/X7W0c).

The Digital Engagement Engine(TM) uses sophisticated data analysis and smart technology, providing companies with the ability to maintain complete control of their content while creating meaningful relationships with new customers.

As a growth-stage company, Electronic Servitor Publication Network is currently acquiring customers. “And again, we are very focused on who we acquire as much as they should be focused on us,” Hager explained. One of the elements XESP expects in potential customers is their capacity and capability to continue to grow. XESP then probes the circumstances and challenges that may have led to slow growth or plateaued operations. And using this knowledge, its technology stack, and managed service, the company implements strategies that unlock the desired growth. “Our Growth as a Service business model is focused on what is most important for our clients—producing results,” Hager continued.

For more information, visit the company’s website at www.XESPN.com.

NOTE TO INVESTORS: The latest news and updates relating to XESP are available in the company’s newsroom at https://ibn.fm/XESP

• Critical elements including graphite have become not only a necessity for economic prosperity but a national security concern for U.S. policymakers
• Graphite is key for the energy transition because of its role in the lithium-ion battery production for EVs, but the U.S. currently has no graphite production capacity
• Reflex Advanced Materials aims to build domestic production and purification of graphite seeking to sell this critical element at a very high price in a very purified form

Critical minerals, such as cobalt, lithium, and nickel, have become more than fundamental building blocks for clean energy technologies and electric vehicle (“EV”) batteries; they have emerged as the linchpin of national security. Domestic battery manufacturing has run into a problem: some raw materials are only found abroad since many of the minerals essential to EV batteries are primarily mined and processed in China or by businesses influenced by China. In a bid to grapple with the U.S. vulnerabilities due to over-reliance on foreign sources, the Biden Administration introduced measures to strengthen domestic critical and rare minerals supply chains, with more than $100 billion invested so far in EV-related manufacturing (https://ibn.fm/OqYoY). Companies like Reflex Advanced Materials (CSE: RFLX) (OTCQB: RFLXF) (FSE: HF2) offer to revive the domestic critical mineral supply chain in a bid to help the nation’s transition to a clean energy future.

A recent White House report revealed the alarming U.S. vulnerabilities stemming from concentrated supply chains of these essential resources. The 2022 U.S. Geological Survey shows that the U.S. relies entirely on imports for twelve critical minerals and more than fifty percent import-dependent on thirty-one additional minerals. China reigns as the largest source of imports for twenty-six of the fifty minerals classified as critical by the U.S. government (https://ibn.fm/i5svH).

Graphite is one such essential resource. As the largest component of the lithium-ion battery, it is essential to energy transition since EV batteries’ anodes are entirely made of this critical mineral. As one of the forms in which carbon is found in nature, it is abundant in the Earth’s crust and, as such, doesn’t appear to be critical. The problem that makes this mineral critical is that the graphite that goes into EV batteries must be processed – and most of these processing facilities are located abroad, mainly in China. For every 10 million EVs manufactured, between 500,000 and one million tons of graphite are needed – an amount that dwarfs the current total global production of graphite of one million tons. Scaling up production is difficult, as is the effort to replace graphite (https://ibn.fm/XUh42).

As a strategic minerals company committed to locating and developing strategic metals and advanced materials projects, Reflex Advanced Materials aims to improve domestic specialty mineral infrastructure efficiencies to meet the soaring demand from North American manufacturers. This British Columbia-based critical minerals producer seeks to position itself as one of the only North American suppliers of high-purity natural graphite for hi-tech applications after the 60-year-long break in the U.S. domestic graphite production. What Reflex believes that separates the company from its competitors, is that it does not target the graphite mass market but is seeking to sell graphite at a very high price in a very purified form. By partnering with the best-in-class companies, Reflex intends to source world-class battery-grade material from the Ruby Deposit in Montana.

A highly dynamic graphite market is expected in 2023, with forecasts indicating an upward price trajectory as the pace for greener energy sources accelerates and the EV revolution gains momentum (https://ibn.fm/hcPxO). Reflex anticipates to gain a robust competitive advantage as U.S. manufacturers continue to demand American supply in the face of heightened geopolitical tensions and legislative support that aims to incentivize domestic supply chains.

For more information, visit the company’s website at www.ReflexMaterials.com.

NOTE TO INVESTORS: The latest news and updates relating to RFLXF are available in the company’s newsroom at https://ibn.fm/RFLXF

• Eloro Resources has recently published its ESG program, the next step on its journey toward creating sustainable long-term value for its shareholders
• The policy lays out the company’s objectives within the fields of corporate governance, corporate social responsibility and environmental production
• Eloro Resources has increasingly looked to align its operations with the requirements of its growing stakeholder base
• The company is set to publish its inaugural ESG report in 2023

Mining companies are increasingly seeking to embed sustainability in the way in which they do business as well as across their corporate strategies. Similarly, Eloro Resources (TSX: ELO) (OTCQX: ELRRF) (FSE: P2QM), an exploration and mine development company with a portfolio of gold and base-metal properties in Bolivia, Peru and Quebec, has recently published its ESG program, setting out its commitment towards creating sustainable long-term value for its shareholders by adhering to the best practices in corporate governance (https://ibn.fm/Yw6vw).

A study carried out by consultancy PwC during the Covid-19 pandemic found that mining companies boasting higher ESG ratings outperformed the broader market, delivering 34 percent average total shareholder returns over the preceding three years – ten percentage points higher than the general market index (https://ibn.fm/Olye5). Improved corporate governance, which tends to manifest itself via superior market returns, can also act as a direct corollary towards increased institutional investor interest. Global ESG-linked assets under management are currently on track to grow to $33.8tn by 2026, up from a mere $18.4tn in 2021 – implying that ESG assets are on course to constitute 21.5% of total global AuM within a span of less than 5 years (https://ibn.fm/SN82x).

Eloro Resources has sought to align its strategy with the interests of its stakeholders, recently elaborating on the measures the company is seeking to undertake within the areas of corporate social responsibility, environmental protection, community engagement, health and safety, and corporate governance. In addition to its broader ESG framework, Eloro has established a set of policies with respect to ethical business practices, personal conduct, competition and fair dealings, and disclosure of information that describe its commitment towards promoting effective functioning of personnel and improving corporate performance (https://ibn.fm/9XpI1).

As a result of the above, all directors, officers, and direct and indirect employees are subject to the company’s anti-bribery and anti-corruption policies. In addition, the company has sought to promote an inclusive culture, in the belief that a board and employee base made up of highly qualified individuals from diverse backgrounds may be a means towards enhancing the corporation’s performance by recognizing and utilizing the diverse combination of skills and talents that such a workforce affords.

Whether it relates to the company’s dedication to the local population – 100% of the on-site team is Bolivian; a commitment towards community empowerment – Eloro sponsors regional schools and sports teams in addition to running technology-focused workshops for women; or, taking the necessary measures to ensure its operations are responsive to the environmental needs of nearby communities, Eloro Resources has increasingly sought to translate its ESG-linked ambitions into practice.

Now and as part of the company’s commitment towards the continuous improvement of its governance practices, Eloro has announced that it is planning to complete and publish the corporation’s inaugural ESG report in 2023 – a milestone that follows the publication of the company’s initial mining resource estimate (“MRE”) in the fourth quarter of 2022.

For more information, visit the company’s website at https://elororesources.com/ or view its ESG policies at https://elororesources.com/esg-program.

NOTE TO INVESTORS: The latest news and updates relating to ELRRF are available in the company’s newsroom at https://ibn.fm/ELRRF

• Ucore Rare Metals Inc. is a critical metals process developer intent on establishing North American-based resources for rare earth element (“REE”) production
• The company has developed its trademarked RapidSX(TM) process for separating REEs from ore deposits, describing it as a faster and more environmentally friendly solution than the industry standard process
• Ucore regards the establishment of a North American-based supply chain for REEs as a critical need to maintain the industry’s independence from China-dominated sourcing and processing
• The U.S. Department of Defense recently awarded Ucore $4 million to demonstrate the capabilities of RapidSX(TM)
• A new NetworkNewsWire (“NNW”) audio broadcast and accompanying editorial outline the efforts of Ucore and a handful of other companies aiming to strengthen North American REE production

More than a decade has passed since the rare earth trades dispute between China, on one side, and several nations including the United States, on the other, erupted over China’s rare earth element (“REE”) export restrictions (https://ibn.fm/0gOCP).

During the interim, the incident has continued to raise alarms as governments and industries search for ways to break China’s iron grip on the global REE supply chain that supplies critical mined resources for modern high-tech devices that range from smartphones and electric vehicle batteries to Abrams tanks and F-35s. An opinion piece published by Fox News in January highlighted the concerns with its headline, “China could shut down our military in a minute if we don’t fix the looming rare earths supply crisis” (https://ibn.fm/gr73H).

China produces 92 percent of the world’s rare earth magnets and performs 85 percent of rare earth processing, as well as 63 percent of rare earth mining (https://ibn.fm/jghLX).

REE processing innovator Ucore Rare Metals (TSX.V: UCU) (OTCQX: UURAF) has been developing technology to disrupt the China-reliant nature of the market, aiming to empower North American industry to extract rare earths from their mined ores using a process superior to the current standard.

An audio broadcast and accompanying editorial recently published by NetworkNewsWire (“NNW”) showcases the efforts of Ucore and a handful of other companies to protect the nations’ access to REEs (https://ibn.fm/GAeEk).

As the editorial notes, Ucore has launched a plant in Canada to demonstrate on a small scale the capabilities of its RapidSX(TM) technology to improve on the standard solvent extraction (“SX”) process for separating REEs from their host ores. And the company is scaling up to commercial production, having acquired a lease for an 80,800 square-foot brownfield facility in Louisiana where it will build its first Strategic Metals Complex (“SMC”) facility for REE separation and oxide production.

The U.S. Department of Defense provided a substantial boost to Ucore’s goals and to the company’s credibility by awarding a $4 million contract to help Ucore demonstrate the effectiveness and America-based capability of its RapidSX(TM) process to the government. Successful completion of the agreement’s requirements could lead to follow-on award opportunities for Ucore to continue its work.

“The full-scale production plant is scheduled to initially process 2,000 tonnes of total rare earth oxides by the end of 2024, increasing to 5,000 tonnes in 2026,” the editorial states (https://ibn.fm/VhoeW). “Management believes that the cost of the company’s facilities will be supported by local and state government incentives as well as prepurchase (off-take) agreements from major manufacturers currently under development. All of this aligns with the final primary purpose of the $4 million DoD contract.”

For more information, visit the company’s website at www.Ucore.com.

NOTE TO INVESTORS: The latest news and updates relating to UURAF are available in the company’s newsroom at https://ibn.fm/UURAF

• Cepton recently revealed that its lidar technology has been deployed to bolster traffic infrastructure in Texas and Utah
• The announcement marks a continued trend, which has seen Cepton’s lidar solutions increasingly used to facilitate traffic management and smart city infrastructure – most recently announcing their multi-million contract with a leading U.S. tolling system operator
• With the company seeing growing business opportunities, as well as being fully committed to executing its flagship lidar series production program by a Top 3 automotive OEM, Cepton has looked to take the next step in its journey with the addition of Luis Gonçalves to its Detroit team
• Gonçalves will join as Director of Customer Programs and will be charged with helping Cepton bolster production volumes whilst simultaneously seeking to exploit new commercial opportunities

Lidar has firmly established its position within in-car technology, but in the city of Arlington, Texas, the technology solution may be on its way towards becoming part of the critical infrastructure on street level. Cepton (NASDAQ: CPTN), a Silicon Valley innovator and pioneer of high-performance MMT(TM) lidar solutions, recently revealed that its lidar technology had been used in a series of groundbreaking studies in Texas and Utah, designed to help improve traffic safety for all road users (https://ibn.fm/8u7Hf). The deployment of lidar technology in Arlington and Irving, Texas as well as in Salt Lake City, Utah has been designed to enable operators to monitor pedestrians’ walking speeds, examine pedestrian and driver adherence to road safety regulations, as well as track ‘near misses’ for pedestrians and vehicles. Going forward, lidar could help city authorities tailor traffic signals to travelers’ needs, potentially allowing for the adjustment of signal timing in real time as well as potentially warning vehicles of potential unseen hazards ahead.

Dr. Jun Pei, CEO of Cepton commented on the deployment of Cepton’s Lidar solutions within the United States’ traffic infrastructure, “Pedestrian safety is essential to people-oriented transportation. We are thrilled that Cepton’s technology has been utilized in such ground-breaking studies and deployments that could revolutionize the way intersections are designed and operated. Our advanced lidar perception solution is designed to provide accurate, real-time 3D analytics that ultimately helps improve the walkability of streets. I am excited to see Helius deployed in more U.S. cities to help transform America’s traffic infrastructure, making safe, smart mobility accessible to everyone.”

Although the use of lidar within road safety infrastructure within the U.S. remains at a relatively nascent stage, the technology has rapidly obtained its acceptance. In early 2022, Cepton announced that its technology was being used to facilitate lidar-based vehicle detection in Cape Town, South Africa. City authorities used Cepton’s lidars to enable pedestrian and vehicle classification. Enabled by lidar, and with an AI platform to understand how both interact with the city environment, allowed for the collection of critical information needed to facilitate both traffic management and urban planning (https://ibn.fm/7IM9W).

In February 2022, Cepton announced a multi-million contract with a leading U.S. tolling system operator, where Cepton lidars will be deployed nationwide to enable accurate and intelligent tolling applications. Cepton has been shipping products to the customer to enable free-flow e-tolling systems on several major tollways located in the Tri-State area and Northern California.

Since its inception in 2016, Cepton has witnessed its innovative lidar based solutions rapidly superseding their original stated goal of facilitating advanced driver assistance systems (“ADAS”) and autonomous vehicle development, with the company’s Helius(TM) Smart Lidar System now also being used to support smart city infrastructure and traffic management systems the world over.

With the company seeking to build upon their recent success, Cepton have just announced the addition of Luis Gonçalves to their Detroit team as the company’s Director of Customer Programs (https://ibn.fm/vjGwD). Boasting extensive experience, having worked at both General Motors and Honda in the past, the industry veteran will be charged with supporting the company’s volume production ramp in support of its lead OEM customers as well as to garner future production awards from other automotive customers.

“Cepton is pioneering the mass-market commercialization of lidar, and I am excited to become part of its vision of enabling safe and autonomous transportation for everyone,” said Gonçalves. “In my previous role at GM, I became very familiar with Cepton lidars through extensive benchmarking and testing efforts on real vehicles, in real-world scenarios. I hope to contribute to Cepton’s successful execution of its flagship lidar program through the production validation and volume production ramp phases this year. I also look forward to applying my learnings from the automotive industry to help solidify Cepton’s next series production award.”

‍For more information, visit the company’s website at www.Cepton.com.

NOTE TO INVESTORS: The latest news and updates relating to CPTN are available in the company’s newsroom at https://ibn.fm/CPTN

GolfLync just received over 200 5-star reviews on the Apple App Store, performing exceptionally well in a space where sports apps averaged 3.97 and social networking apps posted a mere 3.73 in Q2 2022

• The platform matches golfers of all skill levels looking for a game through its smartphone app, becoming the go-to social network for golfers
• The app’s warm reception is seen as a reflection of its exceptional user experience, made possible by the built-in logic that allows users to get the perfect match with whomever they share similar interests and on-course preferences

GolfLync, offering a platform through its smartphone app that matches golfers of all skill levels looking for a game, just affirmed its status as the go-to “social network for golfers” with over 200 5-star ratings on the Apple App Store. The ratings reflect the warm reception the app has received thus far, the level of thoughtfulness and detail that went into its development, and the real user value that GolfLync delivers to the growing community of golf enthusiasts around the country.

Ratings are the way users find the top APPs in a category and GolfLync is significantly higher than the industry average, with sports apps averaging 3.97 and social networking apps posting a mere 3.73 (https://ibn.fm/s38A2). GolfLync delivers an exceptional, tailored experience to golfers which has been instrumental in amassing over 200 5-star reviews on the App Store.

It’s all made possible by the app’s matching logic that connects players that share similar interests with on-course preferences. “[GolfLync] Basically operates like Tinder for golfers,” noted Noah DiPasquale, the Co-Founder, and CEO of GolfLync Inc. “The reason I say the Tinder component is because there is some logic built into it. So if you like to drink on the course, or smoke, or play music, or gamble, you’ll have the opportunity to meet everybody in your area that has similar preferences,” he added (https://ibn.fm/0vitU).

The app is built to help golfers looking to grow their golf network and find other players with similar interests, and setup local groups and events, thus also growing the app’s community. With the popularity of golf having posted a steady rise in recent years, there is a growing demand for a platform that offers such features. GolfLync understands the demand, providing an app that meets users’ personal requirements, and thus driving a positive user experience. The 5-star rating on the App Store reflects an unmatched understanding of the sport while highlighting the company’s commitment to growing the golf community, and the game.

You can download the GolfLync app using the following links:
Android: https://ibn.fm/JjKJQ
iPhone: https://ibn.fm/bGEs7

For more information, visit the company’s website at www.GolfLync.com.

NOTE TO INVESTORS: The latest news and updates relating to GolfLync are available in the company’s newsroom at https://ibn.fm/GOLF

• Biotechnology company BiondVax has entered into a collaboration with Max Planck Institute for Multidisciplinary Sciences (“MPG”) and the University Medical Center Göttingen (“UMG”) to develop innovative NanoAbs
• BiondVax enjoys an exclusive option for an exclusive worldwide license agreement at pre-agreed financial terms for additional NanoAbs discovered and characterized thereunder the RCA
• The company recently announced intent to develop innovative NanoAbs targeting immune system cytokines such as IL-17 for the potential treatment of psoriasis and psoriatic arthritis
• Analysts at Zacks Small-Cap Research laud the shift in focus to anti-IL-17 and have pegged the stock to reach $8 per share from current levels of below $2 per share

Last September, a joint steering committee comprising professionals from BiondVax Pharmaceuticals (NASDAQ: BVXV), the Max Planck Institute for Multidisciplinary Sciences (“MPG”), and the University Medical Center Göttingen (“UMG”), made a decision. Established to guide the BVXV-MPG-UMG NanoAb collaboration, the committee decided to focus the nanosized antibody (“NanoAb”) development on other therapeutic indications in addition to COVID-19. This renewed focus would begin with the development of NanoAbs targeting immune system cytokines such as IL-17 (IL-17A, IL-17F, and IL-17A/F) for the potential treatment of psoriasis and psoriatic arthritis and IL-13 for the potential treatment of asthma (https://ibn.fm/AFw7N).

The committee’s decision is anchored in a five-year definitive research collaboration agreement (“RCA”) entered between BVXV, a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products, and its collaborators, MPG and UMG, allowing the company to exercise an exclusive option for an exclusive worldwide license agreement at pre-agreed financial terms for additional NanoAbs discovered and characterized thereunder (https://ibn.fm/m9LCk).

BiondVax’s decision to focus on developing additional NanoAb therapies was featured in new updated coverage by Zacks Small-Cap Research (https://ibn.fm/mIODn). The research report highlighted the company’s recent announcement regarding its intention to exercise the option to obtain an exclusive license to NanoAbs targeting IL-17 and other system cytokines. This announcement aligns with the company’s de-risked strategy, which includes pursuing biobetter drugs for against biological targets that are already proven to exert beneficial clinical results in humans when treated with conventional monoclonal antibodies (“mAbs”). Additionally, and in line with this strategy, the company intends to capitalize on NanoAbs’ status as potential “bio-betters” that offer potential advantages over mAbs, given their stability, extremely high binding affinity with effective neutralization, and high specificity.

The company has so far gathered significant data about the potential efficacy and capabilities of NanoAbs, thanks to its preclinical in vivo proof-of-concept study evaluating the effect of its inhaled anti-COVID-19 NanoAb therapy. The study, which utilized the industry-standard Syrian hamster model of SARS-CoV-2 infection, showed that the therapy virtually eliminated the virus from the lungs (https://ibn.fm/OHouD), caused milder and shorter illness (https://ibn.fm/nYkMP), and had prophylactic properties (https://ibn.fm/EyuhQ). Based on these encouraging findings, BiondVax is evaluating plans to commence a Phase 1/2a clinical trial, albeit with a keen eye on the mutation of the virus and the emergence of new variants of concern (“VoCs”).

The Zacks report lauds the shift to focus on the anti-IL-17 NanoAb as a “good decision.” By announcing its intention to exercise the option for an additional NanoAb, BiondVax is expanding its pipeline potential while mitigating certain risks to its business and diversifying its portfolio of possible block buster therapies.

Meanwhile, BVXV released its financial results for the first quarter of 2023, reporting cash and cash equivalents of $10.9 million, which analysts at Zacks estimate are sufficient to fund the company’s operations through the first quarter of 2024. An astute business practitioner as well as biotech innovator, BiondVax aims to maximize assets and increase revenues by offering its state-of-the-art cGMP manufacturing services to interested parties which could easily engender new strategic alliances as well as bolster the bottom line.

For more information, visit the company’s website at www.BiondVax.com.

NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://ibn.fm/BVXV

• U.S.-based gene therapy developer Genprex, Inc. is dedicated to finding more effective and novel solutions for battling cancer (particularly lung cancers) and diabetes
• Genprex utilizes a propriety platform that encapsulates tumor-suppressing genes within lipid nanoparticles that are injected intravenously
• The company has received Fast Track designation from the U.S. Food and Drug Administration (“FDA”) for its two non-small cell lung cancer (“NSCLC”) programs using its drug candidate, REQORSA(R)
• Genprex also expects to begin a third trial using its REQORSA therapy against small cell lung cancer (“SCLC”) later this year
• The company recently used its proprietary nanoparticle delivery system, Oncoprex(R), in pre-clinical testing against immunotherapy-resistant tumors, reporting success with a different gene than the one in use for the Fast Tracked programs, thus showing early viability for the use of the Oncoprex platform with a second tumor suppressor gene
• Genprex’s chief medical officer discusses the developments in a new video released by the company May 23

Clinical-stage gene therapy developer Genprex (NASDAQ: GNPX) is expanding the breadth of its drug candidate potential with positive results from a preclinical study that examines the anti-tumor immune response of a gene believed to play a key role in suppressing certain tumors.

Genprex’s lead drug candidate, REQORSA immunogene therapy, uses Genprex’s proprietary, non-viral ONCOPREX Nanoparticle Delivery System to introduce the tumor-suppressing TUSC2 gene through an intravenous injection into cancer patients.

REQORSA is being evaluated in two clinical trials for non-small cell lung cancer (“NSCLC”) patients, and has received Fast Track designation from the U.S. Food and Drug Administration (“FDA”). A third trial for small cell lung cancer (“SCLC”) will begin enrollment this year.

Genprex recently reported positive results from a study using its non-viral ONCOPREX(R) Nanoparticle Delivery System but substituting the NPRL2 gene for the TUSC2 gene (https://ibn.fm/ioHH9).

NPRL2 has long been regarded as a tumor-suppressing gene with potential value in the fight against lung cancers (https://ibn.fm/CyM9u). Genprex’s preclinical study examined the ability to introduce NPRL2 using the ONCOPREX platform into humanized mouse models and to inhibit tumor growth.

“The whole point of our oncology program is to identify tumor suppressor genes, which are systematically deleted during cancer development, and then re-express the tumor suppressor genes in cancers. This process has shown preclinically that it can achieve strong efficacy and is currently being evaluated in Phase 1/2 clinical trials of REQORSA,” Berger said (https://ibn.fm/5c9tg). “Now researchers have replicated that process in in vitro studies with the NPRL2 gene, which we believe is validation that ONCOPREX as a platform may be used with multiple tumor suppressor genes to address multiple types of cancer.” 

The NPRL2 study targeted mouse xenografts KRAS/STK11 mutant anti-PD1 resistant metastatic human non-small cell lung tumors. PD1 is an immune checkpoint that can help tumors resist immunotherapy, thereby promoting tumor progression despite treatment (https://ibn.fm/qCWaC). By successfully using the ONCOPREX delivery system with NPRL2 to target the anti-PD1 resistant tumor cells, these new preclinical data suggest that this could be a new way to treat lung cancer patients progressing on anti-PD1 treatment.

Genprex is developing a gene therapy drug candidate pipeline to battle cancers through its non-viral platform and has a second program to treat Type 1 and Type 2 diabetes using a viral vector.

For more information, visit the company’s website at www.Genprex.com.

NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX

• Fr8Tech’s management recently shared its updated 2023 revenue guidance of $25-30 million, representing as much as nearly 20% growth from the previous year’s full-year revenue
• The growth will be fueled, in part, by the uptake of its services, with the company having posted the highest monthly increase in new client sign-ups since the launch of the Fr8App platform
• Following the recent 10 to 1 reverse share split necessary for Fr8Tech to regain Nasdaq compliance, the company showed that the price would need to show 11x growth on the closing price of March 28, 2023 to meet with third party forecasts for the company
• Fr8Tech remains committed to revolutionizing cross-border shipping, and the recent increase in new client sign-ups is indicative of the building momentum, and potential of its products and services

Freight Technologies (NASDAQ: FRGT) (“Fr8Tech”), a tech company on a mission to revolutionize cross-border shipping by offering carriers increased growth opportunities and shippers with flexibility, visibility, and simplicity, is working hard to have its best year yet. The company’s management recently updated its 2023 revenue guidance of $25-30 million, representing up to nearly 20% growth from the previous year’s full-year revenue (https://ibn.fm/XvYo4) in a very difficult freight market.

This growth will be fueled, in part, by the uptake of its services, with the company having posted the highest monthly increase in new clients since the launch of its Fr8App platform. According to Fr8Tech’s Sales Director, Harry Martin, the new sign-ups were expected to yield a recurring monthly income of over $1 million a month, with the figure expected to start growing in Q2 and through the rest of the year.

“We have onboarded new clients in a variety of sectors, including automotive, beverage, motorcycles, and consumer goods that we had been working on for some time,” noted Mr. Martin.

“The new shipper clients represent a potential for significant recurring traffic on our platform and include leading first-tier automotive clients,” he added.

On March 7, 2023, Fr8Tech announced quarterly revenue for Q4 2022 amounting to $4.4 million. The company also reported a year-to-date (“YTD”) 2022 revenue of an impressive $25.9, representing a 20.6% growth from the previous year. Its management is optimistic that the current momentum will be maintained, yielding even more significant growth as time progresses and more value for its shareholders.

This performance will be very welcome, particularly following the recent 10 to 1 reverse share split necessary for Fr8Tech to regain Nasdaq compliance. As of the close of market on March 31, 2023, this share split saw the share price stand at $1.560, a 92.2% discount to independent analysts’ target price for the company’s ordinary shares of $20 per share on a split-adjusted basis. On the upside, it implied an over 11x growth on the closing price of March 28, 2023.

Fr8Tech remains committed to revolutionizing cross-border shipping, and the recent increase in new client sign-ups indicates the building momentum and potential of its products and services. As it looks forward to a successful year 2023, Fr8Tech continues to strengthen its brand, bolster its offerings, and increase incentives toward its customers. It is a company committed to its mission, taking on a once-complex process of international over-the-road shipping and simplifying it for the ordinary customer.

For more information, visit the company’s website at www.Fr8Technologies.com, and its freight matching platform information site at www.Fr8.App.

NOTE TO INVESTORS: The latest news and updates relating to FRGT are available in the company’s newsroom at https://ibn.fm/FRGT

Corporate Communications
IBN (InvestorBrandNetwork)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
Editor@InvestorBrandNetwork.com